The purpose of this study is to determine the safety, tolerability, and efficacy of natalizumab in individuals diagnosed with active Crohn's Disease that are not in remission (CDAI greater than/equal to 150) and are currently taking Remicade. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease. Patients who complete this study may be eligible for long-term natalizumab therapy via extension protocol ELN100226-351.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
Digestive Disease Associates
Gainesville, Florida, United States
Borland Groover Clinic
Jacksonville, Florida, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Atlanta Gastroenterology Associates
Atlanta, Georgia, United States
University of Kentucky Medical Center
Lexington, Kentucky, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Mercury Street Medical
Butte, Montana, United States
Long Island Clinical Research Associates, LLP
Great Neck, New York, United States
Asheville Gastroenterology
Asheville, North Carolina, United States
Wake Research Associates
Raleigh, North Carolina, United States
Boice-Willis Clinic
Rocky Mount, North Carolina, United States
...and 8 more locations